The purposes of the Pathology Shared Resource are to provide high quality, economical, and fimely pathology-related services to P30 invesfigators and to provide them with a source of human fissues and fluids for invesfigafion. The specific procedures/services provided by the Pathology Shared Resource include histochemical services such as routine histology/histochemistry (e.g., preparing paraffin blocks and H&E slides), special histochemistry, and immunohistochemistry. In addifion the shared resource offers apoptosis (TUNEL) assays and DNA in situ hybridization. Specialized services that have been developed include laser capture microdissection, tissue arrays and photomicroscopy and image analysis. The shared resource has banked tumor samples that are available to investigators without identifiers. In addition to these services, the Pathology Shared Resource provides consultafion and collaborafion with experienced technologists and pathologists.

Public Health Relevance

The mission of the Pathology Shared Resource is to provide technical and professional expertise in the handling of human and animal tissues. By interacting with the shared resource facility, P30 members are educated in how histologic approaches in experimental design can enhance their research. The P30 tissue/tumor bank makes appropriate tissue/tumor bank specimens available to P30 members to generate and test hypotheses in vivo in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-18
Application #
8107450
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
18
Fiscal Year
2010
Total Cost
$49,076
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:
Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203

Showing the most recent 10 out of 989 publications